Krebs Biochemicals & Industries Dirección

Dirección controles de criterios 2/4

El CEO de Krebs Biochemicals & Industries' es Jitendra Shah, nombrado en Aug 2023, tiene una permanencia de menos de un año. posee directamente un 0% de las acciones de la empresa, con un valor de ₹7.14K. La antigüedad media del equipo directivo y de la junta directiva es de 0.8 años y 9.1 años, respectivamente.

Información clave

Jitendra Shah

Chief Executive Officer (CEO)

₹1.9m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.1yrs
Participación del CEO	0.0005%
Permanencia media de la dirección	1.1yrs
Promedio de permanencia en la Junta Directiva	9.3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Jitendra Shah (56 yo)

1.1yrs

Permanencia

₹1,945,000

Compensación

Mr. Jitendra Rameshchandra Shah serves as an Executive Director of Krebs Biochemicals & Industries Limited since August 10, 2023 and served its Additional Non-Executive Director of Krebs Biochemicals & Ind...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jitendra Shah	MD, CEO & Director	1.1yrs	₹1.95m	0.00046% ₹ 8.5k
Ritesh Jain	Chief Financial Officer	1.6yrs	sin datos	sin datos
Rakesh Kalbate	Company Secretary & Compliance Officer	less than a year	sin datos	sin datos

1.1yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 524518 no se considera experimentado ( 0.8 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jitendra Shah	MD, CEO & Director	2.8yrs	₹1.95m	0.00046% ₹ 8.5k
Ravi Tagore	Non-Executive Chairman	31.9yrs	₹70.00k	0.11% ₹ 2.0m
Gundapaneni Venkata Prasad	Independent Non-Executive Director	20yrs	₹90.00k	0.66% ₹ 12.2m
Avinash Ravi	Non-Executive Director	15.6yrs	₹55.00k	9.93% ₹ 183.8m
Pabitra Kumar Bhattacharya	Non-Executive Director	3.2yrs	₹1.10m	0.000020% ₹ 370.4
Satish Khivsara	Independent Non-Executive Director	9.1yrs	₹110.00k	0.0049% ₹ 90.2k
Malati Tangirala	Independent Non-Executive Director	9.6yrs	₹90.00k	sin datos
Raj Kamal Verma	Independent Non-Executive Director	8.6yrs	₹45.00k	0.00097% ₹ 18.0k

9.3yrs

Permanencia media

71yo

Promedio de edad

Junta con experiencia: La junta directiva de 524518 se considera experimentada (8.9 años de antigüedad promedio).

Krebs Biochemicals & Industries Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Krebs Biochemicals & Industries Limited, Annual General Meeting, Sep 27, 2024

Insufficient new directors

Krebs Biochemicals & Industries Limited Appoints Keyur Doshi as Company Secretary, Compliance Officer

Krebs Biochemicals & Industries Limited Announces Resignation of Rohit Taparia as Company Secretary and Compliance Officer

Krebs Biochemicals & Industries Limited, Annual General Meeting, Sep 27, 2023

Krebs Biochemicals & Industries Limited Approves CFO Changes

Recent updates

Krebs Biochemicals & Industries Limited, Annual General Meeting, Sep 27, 2024

First quarter 2025 earnings released: ₹2.40 loss per share (vs ₹2.47 loss in 1Q 2024)

Insufficient new directors

Krebs Biochemicals & Industries Limited to Report Q1, 2025 Results on Aug 07, 2024

Full year 2024 earnings released: ₹9.16 loss per share (vs ₹11.45 loss in FY 2023)

Krebs Biochemicals & Industries Limited to Report Q4, 2024 Results on May 21, 2024

Third quarter 2024 earnings released: ₹2.31 loss per share (vs ₹2.58 loss in 3Q 2023)

Krebs Biochemicals & Industries Limited to Report Q3, 2024 Results on Feb 12, 2024

Krebs Biochemicals & Industries Limited Appoints Keyur Doshi as Company Secretary, Compliance Officer

New minor risk - Share price stability

Second quarter 2024 earnings released: ₹1.66 loss per share (vs ₹1.88 loss in 2Q 2023)

Krebs Biochemicals & Industries Limited Announces Resignation of Rohit Taparia as Company Secretary and Compliance Officer

Krebs Biochemicals & Industries Limited to Report Q2, 2024 Results on Nov 08, 2023

Krebs Biochemicals & Industries Limited, Annual General Meeting, Sep 27, 2023

First quarter 2024 earnings released: ₹2.47 loss per share (vs ₹3.77 loss in 1Q 2023)

Krebs Biochemicals & Industries Limited to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings released: ₹11.30 loss per share (vs ₹20.65 loss in FY 2022)

Krebs Biochemicals & Industries Limited to Report Q4, 2023 Results on May 24, 2023

Third quarter 2023 earnings released: ₹2.58 loss per share (vs ₹6.00 loss in 3Q 2022)

Krebs Biochemicals & Industries Limited Approves CFO Changes

Krebs Biochemicals & Industries Limited to Report Q3, 2023 Results on Feb 03, 2023

Second quarter 2023 earnings released: ₹1.88 loss per share (vs ₹5.05 loss in 2Q 2022)

Second quarter 2023 earnings released: ₹1.88 loss per share (vs ₹5.05 loss in 2Q 2022)

Krebs Biochemicals & Industries Limited to Report Q2, 2023 Results on Nov 10, 2022

Krebs Biochemicals & Industries Limited, Annual General Meeting, Sep 30, 2022

First quarter 2023 earnings released: ₹3.77 loss per share (vs ₹4.37 loss in 1Q 2022)

Taruni Banda Resigns as Company Secretary and Compliance Officer of Krebs Biochemicals & Industries Limited, Effective from August 6, 2022

Krebs Biochemicals & Industries Limited to Report Q1, 2023 Results on Aug 01, 2022

Full year 2022 earnings released: ₹21.21 loss per share (vs ₹14.45 loss in FY 2021)

Krebs Biochemicals & Industries Limited to Report Q4, 2022 Results on May 23, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: ₹5.05 loss per share (vs ₹3.26 loss in 2Q 2021)

Non-Executive Director Manish Jain has left the company

First quarter 2022 earnings released: ₹4.37 loss per share (vs ₹3.43 loss in 1Q 2021)

Full year 2021 earnings released: ₹14.53 loss per share (vs ₹16.04 loss in FY 2020)

Third quarter 2021 earnings released: ₹4.21 loss per share (vs ₹4.60 loss in 3Q 2020)

Krebs Biochemicals & Industries Limited to Report Q3, 2021 Results on Jan 30, 2021

New 90-day high: ₹137

New 90-day high: ₹94.45

Krebs Biochemicals & Industries Limited to Report Q2, 2021 Results on Nov 05, 2020

Krebs Biochemicals & Industries Limited to Report Q1, 2021 Results on Aug 07, 2020

Earnings released

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad